From the beginning of its membership in NIDA's Clinical Trials Network (CTN) in 2000, the Ohio Valley Node (OVN) has been an effective, enthusiastic, and energetic node that has excelled in providing scientific and administrative leadership, in collaborating with other nodes and with NIDA and contract staff, and in disseminating information about evidence-based practices and the results of CTN studies. The OVN's Community Treatment Programs (CTPs) and its Regional Research and Training Center (RRTC) have worked together to create a node in which the CTN's goal of bilateral communication/collaboration between researchers and treatment providers has been fully realized. The success in integrating all members of this geographically dispersed node into a unified whole, together with the strong commitment of the Node PI, CTP PIs, and RRTC staff to full participation in the CTN, have enabled the OVN to be extremely productive throughout its membership in the CYN. The OVN has an experienced staff, including several RRTC and CTP PIs who have been with the OVN since its formation. The OVN continues to collaborate with a growing number of CTPs which have a variety of patient characteristics and extend over a broad geographical range now encompassing the entire Midwest (12 states) and the Upper-South states of Kentucky, Tennessee, and West Virginia. The 23 OVN CTPs, which together receive more than 100,000 patient visits a year, will contribute significantly to the number and variety of potential participants for CTN studies. The OVN administrative and management plans for the next five years capitalize on the strengths of the OVN: experience, teamwork, and varied areas of expertise (including HIV/AIDS, emergency medicine, integration of addiction treatment into primary care, and telemedicine), so the OVN can continue to contribute scientific leadership and excellence in developing/conducting CTN protocols. The OVN has detailed a research agenda designed to improve opioid dependence treatment by optimizing medication-assisted treatment and expanding office-based opioid treatment. Already cooperating actively with the four Addiction Technology and Transfer Centers (ATTCs) associated with the states covered by the OVN, the Node plans to strengthen relationships with other networks (e.g., Cincinnati Center for Clinical &Translational Science &Training).

Public Health Relevance

To further the goal of expanding substance abuse care and research into non-traditional settings, Ohio Valley Node Community Treatment Programs now include an HIV/AIDS clinic, two primary care centers, and two hospital emergency departments. The Ohio Valley Node's research agenda is designed to improve opioid dependence treatment by optimizing medication-assisted treatment and expanding office-based opioid treatment, including a new mechanism for dosing buprenorphine which would reduce diversion.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10DA013732-13S2
Application #
8656498
Study Section
Special Emphasis Panel (ZDA1-KXH-C (04))
Program Officer
Dobbins, Ronald
Project Start
2000-09-30
Project End
2015-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
13
Fiscal Year
2013
Total Cost
$688,350
Indirect Cost
$97,476
Name
University of Cincinnati
Department
Psychiatry
Type
Schools of Medicine
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Gooden, Lauren; Metsch, Lisa R; Pereyra, Margaret R et al. (2016) Examining the Efficacy of HIV Risk-Reduction Counseling on the Sexual Risk Behaviors of a National Sample of Drug Abuse Treatment Clients: Analysis of Subgroups. AIDS Behav 20:1893-906
Hernández, Diana; Feaster, Daniel J; Gooden, Lauren et al. (2016) Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients. AIDS Behav 20:204-14
Murphy, Sean M; Campbell, Aimee N C; Ghitza, Udi E et al. (2016) Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial. Drug Alcohol Depend 161:119-26
Magee, Joshua C; Lewis, Daniel F; Winhusen, Theresa (2016) Evaluating Nicotine Craving, Withdrawal, and Substance Use as Mediators of Smoking Cessation in Cocaine- and Methamphetamine-Dependent Patients. Nicotine Tob Res 18:1196-201
Magee, Joshua C; Winhusen, Theresa (2016) The coupling of nicotine and stimulant craving during treatment for stimulant dependence. J Consult Clin Psychol 84:230-7
Adinoff, Bryon; Carmody, Thomas J; Walker, Robrina et al. (2016) Decision-making processes as predictors of relapse and subsequent use in stimulant-dependent patients. Am J Drug Alcohol Abuse 42:88-97
Metsch, Lisa R; Feaster, Daniel J; Gooden, Lauren et al. (2016) Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial. JAMA 316:156-70
Haney, Margaret; Malcolm, Robert J; Babalonis, Shanna et al. (2016) Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. Neuropsychopharmacology 41:1974-82
McClure, Erin A; Campbell, Aimee N C; Pavlicova, Martina et al. (2015) Cigarette Smoking During Substance Use Disorder Treatment: Secondary Outcomes from a National Drug Abuse Treatment Clinical Trials Network study. J Subst Abuse Treat 53:39-46
Sanchez, Katherine; Walker, Robrina; Campbell, Aimee N C et al. (2015) Depressive Symptoms and Associated Clinical Characteristics in Outpatients Seeking Community-Based Treatment for Alcohol and Drug Problems. Subst Abus 36:297-303

Showing the most recent 10 out of 114 publications